{
  "meta": {
    "title": "Chronic_Kidney_Disease_Renal_Transplantation",
    "url": "https://brainandscalpel.vercel.app/chronic-kidney-disease-renal-transplantation-7a8dd9ad.html",
    "scrapedAt": "2025-11-29T18:25:05.053Z"
  },
  "questions": [
    {
      "id": 20416,
      "choices": [
        {
          "id": 81625,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Improved renal function </span></span></span></p>"
        },
        {
          "id": 81626,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glomerulosclerosis </span></span></span></p>"
        },
        {
          "id": 81627,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased renal blood flow </span></span></span></p>"
        },
        {
          "id": 81628,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased intrarenal pressure</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In CKD, the remaining nephrons undergo hyperfiltration and hypertrophy to compensate for lost renal mass. Which of the following is a long-term consequence of these adaptations?</span></span></p>",
      "unique_key": "Q3734304",
      "question_audio": null,
      "question_video": null,
      "map_id": 20413,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Glomerulosclerosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While hyperfiltration and hypertrophy initially help maintain GFR, they lead to increased glomerular capillary pressure and shear stress. Over time, this results in glomerular damage, sclerosis, and ultimately, further nephron loss, accelerating CKD progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Improved renal function:</span></strong><span style=\"font-size:12.0pt\"> Hyperfiltration and hypertrophy only temporarily maintain GFR and eventually lead to decline.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased renal blood flow:</span></strong><span style=\"font-size:12.0pt\"> While blood flow initially increases, it eventually decreases as nephrons are lost.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Decreased intrarenal pressure:</span></strong><span style=\"font-size:12.0pt\"> Intrarenal pressure actually increases due to hyperfiltration, contributing to damage</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand that while hyperfiltration and hypertrophy are initially compensatory mechanisms in chronic kidney disease (CKD), they ultimately lead to glomerulosclerosis and progressive decline in renal function. Recognizing this pathophysiological process highlights the importance of early intervention and management to slow down the progression of CKD.</span></span></span></p>",
      "correct_choice_id": 81626,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20417,
      "choices": [
        {
          "id": 81629,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Diabetic nephropathy </span></span></span></p>"
        },
        {
          "id": 81630,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hypertensive nephrosclerosis </span></span></span></p>"
        },
        {
          "id": 81631,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Lupus nephritis </span></span></span></p>"
        },
        {
          "id": 81632,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">IgA nephropathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a 10-year history of systemic lupus erythematosus (SLE) presents with fatigue, edema, and hypertension. Laboratory tests reveal proteinuria and an estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73m2. Which of the following is the most likely cause of her chronic kidney disease (CKD)?</span></span></p>",
      "unique_key": "Q2209498",
      "question_audio": null,
      "question_video": null,
      "map_id": 20414,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Lupus nephritis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lupus nephritis is a common complication of SLE and can lead to CKD. The patient&#39;s history of SLE, proteinuria, and declining eGFR strongly suggest this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Diabetic nephropathy</span></strong><span style=\"font-size:12.0pt\">: Diabetic nephropathy is not associated with SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypertensive nephrosclerosis</span></strong><span style=\"font-size:12.0pt\">: While hypertension can contribute to CKD, it&#39;s less likely to be the primary cause in a young patient with SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IgA nephropathy</span></strong><span style=\"font-size:12.0pt\">: IgA nephropathy typically presents with recurrent hematuria, not the constellation of symptoms seen here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To recognize lupus nephritis as a common and potentially serious complication of systemic lupus erythematosus (SLE). Early detection and management are crucial to preventing the progression of lupus nephritis to chronic kidney disease (CKD) and end-stage renal disease (ESRD).</span></span></span></p>",
      "correct_choice_id": 81631,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20418,
      "choices": [
        {
          "id": 81633,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CVD is the leading cause of death in patients with CKD. </span></span></span></p>"
        },
        {
          "id": 81634,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The risk of CVD decreases as CKD progresses. </span></span></span></p>"
        },
        {
          "id": 81635,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Traditional CVD risk factors are not important in CKD patients. </span></span></span></p>"
        },
        {
          "id": 81636,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early-stage CKD patients do not require CVD screening.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about cardiovascular disease (CVD) in chronic kidney disease (CKD) is TRUE?</span></span></p>",
      "unique_key": "Q4271201",
      "question_audio": null,
      "question_video": null,
      "map_id": 20415,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) CVD is the leading cause of death in patients with CKD.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CVD is the most common cause of death in CKD patients, often occurring before they reach end-stage renal disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. The risk of CVD decreases as CKD progresses</span></strong><span style=\"font-size:12.0pt\">: The risk of CVD increases as CKD progresses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Traditional CVD risk factors are not important in CKD patients</span></strong><span style=\"font-size:12.0pt\">: Traditional CVD risk factors are important, but CKD-specific risk factors must also be considered.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Early-stage CKD patients do not require CVD screening</span></strong><span style=\"font-size:12.0pt\">: Early CVD screening and prevention are crucial in CKD patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand the significant impact of cardiovascular disease (CVD) on patients with chronic kidney disease (CKD). It is crucial to recognize that CVD is the leading cause of death in this population and that the risk increases as CKD progresses. This knowledge highlights the importance of early CVD screening and aggressive management of both traditional and CKD-specific risk factors to improve outcomes for patients with CKD.</span></span></span></p>",
      "correct_choice_id": 81633,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20419,
      "choices": [
        {
          "id": 81637,
          "text": "<p><span style=\"font-size:12.0pt;\">G2A2</span></p>"
        },
        {
          "id": 81638,
          "text": "<p><span style=\"font-size:12.0pt;\">G3aA2</span></p>"
        },
        {
          "id": 81639,
          "text": "<p><span style=\"font-size:12.0pt;\">G3bA2</span></p>"
        },
        {
          "id": 81640,
          "text": "<p><span style=\"font-size:12.0pt;\">G4A2</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old patient presents with a GFR of 50 mL/min/1.73m² and an albuminuria level of 150 mg/g. According to the KDIGO 2012 classification, what is the patient's CKD stage?</span></p>",
      "unique_key": "Q1089123",
      "question_audio": null,
      "question_video": null,
      "map_id": 20416,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Correct Answer: B) G3aA2</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">According to the KDIGO 2012 classification, CKD staging is determined by both GFR levels and albuminuria categories. With a GFR of 50 mL/min/1.73m², this patient falls into the G3a category (45-59 mL/min/1.73m²), which represents \"mildly to moderately decreased\" kidney function. The albuminuria level of 150 mg/g places the patient in the A2 category (30-300 mg/g), representing \"moderately increased\" albuminuria. Together, these values classify the patient as G3aA2.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A) G2A2</strong> - This is incorrect because while the albuminuria category (A2) is appropriate, the GFR of 50 mL/min/1.73m² does not fall into G2 range, which is 60-89 mL/min/1.73m².</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C) G3bA2</strong> - This is incorrect because G3b represents a GFR range of 30-44 mL/min/1.73m². The patient's GFR of 50 mL/min/1.73m² is higher than this range and falls into G3a instead.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D) G4A2</strong> - This is incorrect because G4 represents a GFR range of 15-29 mL/min/1.73m², indicating severely decreased kidney function. The patient's GFR of 50 mL/min/1.73m² is substantially higher and does not indicate this level of severity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The KDIGO 2012 classification system evaluates CKD by incorporating both GFR and albuminuria levels, providing a more comprehensive assessment of kidney disease severity and progression risk than GFR alone.</span></p>",
      "correct_choice_id": 81638,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20420,
      "choices": [
        {
          "id": 81641,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pericardial friction rub </span></span></span></p>"
        },
        {
          "id": 81642,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PR depression on ECG </span></span></span></p>"
        },
        {
          "id": 81643,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated troponin levels </span></span></span></p>"
        },
        {
          "id": 81644,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diffuse ST-segment elevation on ECG</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a typical finding in uremic pericarditis?</span></span></p>",
      "unique_key": "Q3793405",
      "question_audio": null,
      "question_video": null,
      "map_id": 20417,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Elevated troponin levels</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Uremic pericarditis is not associated with myocardial damage, so troponin levels should be normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pericardial friction rub</span></strong><span style=\"font-size:12.0pt\">, <strong>Option B. PR depression on ECG</strong> and <strong>Option D.</strong></span> <strong><span style=\"font-size:12.0pt\">Diffuse ST-segment elevation on ECG</span></strong><span style=\"font-size:12.0pt\">: These are classic findings in uremic pericarditis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand the typical findings in uremic pericarditis, including pericardial friction rub, PR depression on ECG, and diffuse ST-segment elevation on ECG. It is important to recognize that elevated troponin levels are not a typical finding in uremic pericarditis, as it is not associated with myocardial damage.</span></span></span></p>",
      "correct_choice_id": 81643,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20421,
      "choices": [
        {
          "id": 81645,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated BUN and creatinine </span></span></span></p>"
        },
        {
          "id": 81646,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperphosphatemia </span></span></span></p>"
        },
        {
          "id": 81647,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Uremic toxin accumulation </span></span></span></p>"
        },
        {
          "id": 81648,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metabolic acidosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with CKD stage 5 presents with asterixis, pericarditis, and platelet dysfunction. Which of the following is the most likely explanation for these findings?</span></span></p>",
      "unique_key": "Q9273338",
      "question_audio": null,
      "question_video": null,
      "map_id": 20418,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Uremic toxin accumulation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Asterixis, pericarditis, and platelet dysfunction are all classic manifestations of uremia, caused by the buildup of various uremic toxins in the body when kidney function is severely impaired.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Elevated BUN and creatinine</span></strong><span style=\"font-size:12.0pt\">: BUN and creatinine are markers of kidney function but don&#39;t directly cause these specific symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hyperphosphatemia</span></strong><span style=\"font-size:12.0pt\">: Hyperphosphatemia is a complication of CKD but is not the primary cause of these symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metabolic acidosis</span></strong><span style=\"font-size:12.0pt\">: Metabolic acidosis can contribute to uremic symptoms but is not the sole cause of these specific findings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To recognize the classic manifestations of uremia, such as asterixis, pericarditis, and platelet dysfunction. These symptoms are caused by the accumulation of uremic toxins in the body due to severely impaired kidney function. Understanding this pathophysiology is crucial for early diagnosis and management of uremia in patients with chronic kidney disease (CKD).</span></span></span></p>",
      "correct_choice_id": 81647,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20422,
      "choices": [
        {
          "id": 81649,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 deficiency </span></span></span></p>"
        },
        {
          "id": 81650,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency </span></span></span></p>"
        },
        {
          "id": 81651,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased erythropoietin production </span></span></span></p>"
        },
        {
          "id": 81652,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folate deficiency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old male with stage 4 CKD presents with fatigue and dyspnea on exertion. His hemoglobin level is 9.5 g/dL. Which of the following is the most likely cause of his anemia?</span></span></p>",
      "unique_key": "Q5191680",
      "question_audio": null,
      "question_video": null,
      "map_id": 20419,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Decreased erythropoietin production</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The primary cause of anemia in CKD is decreased erythropoietin (EPO) production due to kidney damage. EPO is a hormone produced by the kidneys that stimulates red blood cell production in the bone marrow. In healthy individuals, the kidneys release EPO in response to low blood oxygen levels. When the kidneys are damaged, they produce less EPO, leading to a decrease in red blood cell production and anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Vitamin B12 deficiency&nbsp;</span></strong><span style=\"font-size:12.0pt\">and <strong>Option D. folate deficiency</strong>:<strong> </strong>Can also cause anemia, but they are less common causes of anemia in CKD. These deficiencies can be ruled out with blood tests.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Iron deficiency: </span></strong><span style=\"font-size:12.0pt\">Iron deficiency can contribute to anemia in some patients with CKD, but it is not the primary cause. Iron stores are usually assessed before starting treatment for anemia in CKD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand that the primary cause of anemia in chronic kidney disease (CKD) is decreased erythropoietin (EPO) production due to kidney damage. This knowledge is essential for the accurate diagnosis and management of anemia in CKD patients, as it guides the choice of treatment, which often involves administering erythropoiesis-stimulating agents (ESAs) to compensate for the lack of endogenous EPO.</span></span></span></p>",
      "correct_choice_id": 81651,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20423,
      "choices": [
        {
          "id": 81653,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Calcium carbonate </span></span></span></p>"
        },
        {
          "id": 81654,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Sevelamer </span></span></span></p>"
        },
        {
          "id": 81655,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Cinacalcet </span></span></span></p>"
        },
        {
          "id": 81656,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcitriol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications directly suppresses PTH secretion in CKD patients with secondary hyperparathyroidism?</span></span></p>",
      "unique_key": "Q9575869",
      "question_audio": null,
      "question_video": null,
      "map_id": 20420,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Calcitriol</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcitriol (active vitamin D) directly suppresses PTH secretion and is used in the management of secondary hyperparathyroidism in CKD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Calcium carbonate</span></strong><span style=\"font-size:12.0pt\">: Calcium carbonate is a phosphate binder,&nbsp;not a PTH suppressant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sevelamer</span></strong><span style=\"font-size:12.0pt\">: Sevelamer is a phosphate binder,&nbsp;not a PTH suppressant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cinacalcet</span></strong><span style=\"font-size:12.0pt\">: Cinacalcet is a calcimimetic that increases the sensitivity of the parathyroid gland to calcium,&nbsp;indirectly lowering PTH</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand the different classes of medications used to manage secondary hyperparathyroidism in chronic kidney disease (CKD), and to recognize that calcitriol is the only medication listed that directly suppresses parathyroid hormone (PTH) secretion.</span></span></span></p>",
      "correct_choice_id": 81656,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20424,
      "choices": [
        {
          "id": 81657,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No treatment is necessary at this time</span></span></span></p>"
        },
        {
          "id": 81658,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate calcium carbonate </span></span></span></p>"
        },
        {
          "id": 81659,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate calcitriol </span></span></span></p>"
        },
        {
          "id": 81660,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate cinacalcet</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with CKD stage 3 has a PTH level of 150 pg/mL and a normal serum calcium level. Which of the following is the most appropriate management strategy?</span></span></p>",
      "unique_key": "Q8367635",
      "question_audio": null,
      "question_video": null,
      "map_id": 20421,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) No treatment is necessary at this time</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to current guidelines, a PTH level within 2-9 times the upper limit of normal is acceptable, especially if calcium levels are normal. Therefore, no treatment is indicated at this time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Initiate calcium carbonate</span></strong><span style=\"font-size:12.0pt\">, <strong>Option C. Initiate calcitriol </strong>and <strong>Option D.</strong> <strong>Initiate</strong> <strong>cinacalcet</strong>: These medications are not indicated unless PTH levels exceed the target range or there are other complications of CKD-MBD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand that not all elevated PTH levels in CKD require immediate intervention. Treatment decisions should be based on the severity of PTH elevation, calcium levels, and the presence of other complications of CKD-mineral bone disease (CKD-MBD).</span></span></span></p>",
      "correct_choice_id": 81657,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20425,
      "choices": [
        {
          "id": 81661,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcium supplements may worsen it. </span></span></span></p>"
        },
        {
          "id": 81662,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blood vessel blockage is involved. </span></span></span></p>"
        },
        {
          "id": 81663,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pseudomonas infection is common. </span></span></span></p>"
        },
        {
          "id": 81664,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Warfarin use is a risk factor.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 63-year-old woman with kidney failure on dialysis develops a rapidly progressing, painful nodule on her abdomen that breaks down and forms an open sore (see image). She takes medications for high blood pressure (losartan) and blood clots (warfarin). Which of the following is LEAST likely about her condition?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-174056.png\" style=\"height:174px; width:300px\" /></span></span></p>",
      "unique_key": "Q8062224",
      "question_audio": null,
      "question_video": null,
      "map_id": 20422,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pseudomonas infection is common.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pseudomonas co-infection is typical&nbsp;</span></strong><span style=\"font-size:12.0pt\">is Incorrect. While infection can occur in ulcerated lesions, <em>Staphylococcus aureus</em> is more commonly implicated than Pseudomonas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Calcium supplements may worsen it:</span></strong><span style=\"font-size:12.0pt\"> True. Calcium-based phosphate binders and vitamin D analogs can contribute to the development of calciphylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Calcium supplements may worsen it:</span></strong><span style=\"font-size:12.0pt\"> True. Calciphylaxis is characterized by calcification of small blood vessels leading to ischemia and necrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Warfarin use is a risk factor:</span></strong><span style=\"font-size:12.0pt\"> True. Warfarin is associated with an increased risk of calciphylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand the key features and risk factors associated with calciphylaxis, a rare but severe complication of chronic kidney disease (CKD). It is important to recognize that while Pseudomonas infection can occur in any open wound, it is not the most common pathogen associated with calciphylaxis. Staphylococcus aureus is more frequently implicated in these infections.</span></span></span></p>",
      "correct_choice_id": 81663,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20426,
      "choices": [
        {
          "id": 81665,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension </span></span></span></p>"
        },
        {
          "id": 81666,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flank or back pain </span></span></span></p>"
        },
        {
          "id": 81667,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gross hematuria </span></span></span></p>"
        },
        {
          "id": 81668,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urinary tract infection</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common presenting symptom in patients with ADPKD?</span></span></p>",
      "unique_key": "Q2235102",
      "question_audio": null,
      "question_video": null,
      "map_id": 20423,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Flank or back pain</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flank or back pain is the most common presenting symptom in ADPKD, often due to cyst enlargement, hemorrhage, or infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hypertension</span></strong><span style=\"font-size:12.0pt\">: Hypertension is common but may not be the initial presenting symptom.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Gross hematuria</span></strong><span style=\"font-size:12.0pt\">: Gross hematuria occurs in a significant proportion of patients but is less common than pain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Urinary tract infection</span></strong><span style=\"font-size:12.0pt\">: Urinary tract infections are a complication but not the most common initial presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To recognize that flank or back pain is the most common presenting symptom in autosomal dominant polycystic kidney disease (ADPKD). This pain is often due to cyst enlargement, hemorrhage, or infection and may be the first sign of the disease.</span></span></span></p>",
      "correct_choice_id": 81666,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20427,
      "choices": [
        {
          "id": 81669,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Tolvaptan </span></span></span></p>"
        },
        {
          "id": 81670,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Everolimus </span></span></span></p>"
        },
        {
          "id": 81671,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Octreotide </span></span></span></p>"
        },
        {
          "id": 81672,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Cinacalcet</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications is FDA-approved for slowing kidney disease progression in ADPKD?</span></span></p>",
      "unique_key": "Q4839429",
      "question_audio": null,
      "question_video": null,
      "map_id": 20424,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Tolvaptan</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tolvaptan is a vasopressin receptor antagonist that has been shown to slow kidney cyst growth and decline in kidney function in ADPKD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Everolimus</span></strong><span style=\"font-size:12.0pt\">: Everolimus is an mTOR inhibitor under investigation but not FDA-approved for ADPKD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Octreotide</span></strong><span style=\"font-size:12.0pt\">: Octreotide is a somatostatin analogue with potential benefits but not FDA-approved.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12pt\">Option D.</span><span style=\"font-size:14.6667px\">&nbsp;</span></strong><strong style=\"font-size:11pt\"><span style=\"font-size:12.0pt\">Cinacalcet</span></strong><span style=\"font-size:12pt\">: Cinacalcet is used to treat secondary hyperparathyroidism in CKD</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand that tolvaptan is the only FDA-approved medication for slowing the progression of kidney disease in ADPKD. It works by inhibiting vasopressin, which plays a role in cyst growth.</span></span></span></p>",
      "correct_choice_id": 81669,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20428,
      "choices": [
        {
          "id": 81673,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brachiocephalic AVF </span></span></span></p>"
        },
        {
          "id": 81674,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Radiocephalic AVF </span></span></span></p>"
        },
        {
          "id": 81675,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brachiobasilic AVF </span></span></span></p>"
        },
        {
          "id": 81676,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Femoral AVF</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old end-stage renal disease (ESRD) patient requires hemodialysis access. Given the need for long-term vascular access, which arteriovenous fistula (AVF) would be the most suitable choice for this patient?</span></span></p>",
      "unique_key": "Q3041825",
      "question_audio": null,
      "question_video": null,
      "map_id": 20425,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Radiocephalic AVF</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For creating a permanent hemodialysis access, a radiocephalic AVF at the wrist is the gold standard choice among nephrologists due to several advantages:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Preservation of future access sites:</span></strong><span style=\"font-size:12.0pt\"> The radial artery and cephalic vein are distal vessels, leaving the brachial artery and basilic vein available for potential future fistula creation if needed.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Lower complication rates:</span></strong><span style=\"font-size:12.0pt\"> Compared to other AVFs, radiocephalic AVFs have a lower risk of complications.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Easier cannulation:</span></strong><span style=\"font-size:12.0pt\"> The radial artery and cephalic vein are typically more superficial and easily accessible for needle insertion during hemodialysis procedures.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Brachiocephalic AVF&nbsp;</span></strong><span style=\"font-size:12.0pt\">and <strong>Option C. Brachiobasilic AVF</strong>: Larger vessels, higher flow, risk of steal syndrome/heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Femoral AVF</span></strong><span style=\"font-size:12.0pt\">: Higher infection risk, deeper cannulation</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand the importance of choosing the most suitable arteriovenous fistula (AVF) for long-term hemodialysis access. The radiocephalic AVF at the wrist is generally preferred due to its lower complication rates, easier cannulation, and preservation of future access sites.</span></span></span></p>",
      "correct_choice_id": 81674,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20429,
      "choices": [
        {
          "id": 81677,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blood flow rate </span></span></span></p>"
        },
        {
          "id": 81678,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dialysate flow rate </span></span></span></p>"
        },
        {
          "id": 81679,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dialyzer characteristics </span></span></span></p>"
        },
        {
          "id": 81680,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patient&#39;s age</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a determinant of hemodialysis efficiency?</span></span></p>",
      "unique_key": "Q4185102",
      "question_audio": null,
      "question_video": null,
      "map_id": 20426,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Patient&#39;s age</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While patient&#39;s age can influence dialysis needs in some ways, it doesn&#39;t directly affect the efficiency of the hemodialysis process itself. Here&#39;s why the other options are important determinants of hemodialysis efficiency:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Blood flow rate:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Higher blood flow rates allow for greater clearance of solutes from the bloodstream across the dialyzer membrane.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dialysate flow rate:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Faster dialysate flow rates create a steeper concentration gradient between the blood and dialysate, enhancing the diffusion of solutes from the blood into the dialysate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dialyzer characteristics:</span></strong><span style=\"font-size:12.0pt\">&nbsp;The dialyzer membrane&#39;s surface area, porosity, and permeability all influence how effectively solutes are removed from the blood. For instance, a larger surface area allows for more clearance of solutes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To recognize the key factors that determine hemodialysis efficiency, including blood flow rate, dialysate flow rate, and dialyzer characteristics. While a patient&#39;s age can influence their overall dialysis needs, it doesn&#39;t directly affect the efficiency of the hemodialysis process itself.</span></span></span></p>",
      "correct_choice_id": 81680,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20430,
      "choices": [
        {
          "id": 81681,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cloudy dialysate </span></span></span></p>"
        },
        {
          "id": 81682,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abdominal pain </span></span></span></p>"
        },
        {
          "id": 81683,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fever </span></span></span></p>"
        },
        {
          "id": 81684,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypotension</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following findings is NOT typically associated with peritonitis in peritoneal dialysis?</span></span></p>",
      "unique_key": "Q2644229",
      "question_audio": null,
      "question_video": null,
      "map_id": 20427,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hypotension</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While hypotension can occur in severe sepsis, it is not a typical finding in PD peritonitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12pt\">Option A.</span><span style=\"font-size:14.6667px\">&nbsp;</span></strong><strong style=\"font-size:11pt\"><span style=\"font-size:12.0pt\">Cloudy dialysate,&nbsp;Option B. Abdominal pain&nbsp;</span></strong><span style=\"font-size:12pt\">and&nbsp;<strong>Option C. Fever</strong>: Cloudy dialysate,&nbsp;abdominal pain,&nbsp;and fever are classic signs of peritonitis.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand the typical clinical presentation of peritonitis in peritoneal dialysis, including cloudy dialysate, abdominal pain, and fever. Recognizing these signs and symptoms is crucial for early diagnosis and treatment to prevent complications.</span></span></span></p>",
      "correct_choice_id": 81684,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20431,
      "choices": [
        {
          "id": 81685,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute intradialytic hypotension </span></span></span></p>"
        },
        {
          "id": 81686,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemodialysis-associated thrombosis </span></span></span></p>"
        },
        {
          "id": 81687,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dialysis disequilibrium syndrome </span></span></span></p>"
        },
        {
          "id": 81688,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Air embolism during hemodialysis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old man with end-stage renal disease and uremia starts hemodialysis. During the session, he becomes restless, confused, and develops a headache. Which of the following is the most likely cause of his symptoms?</span></span></p>",
      "unique_key": "Q8501243",
      "question_audio": null,
      "question_video": null,
      "map_id": 20428,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Dialysis disequilibrium syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The rapid removal of urea during hemodialysis in a uremic patient can cause an osmotic gradient between the brain and blood, leading to cerebral edema and the neurologic symptoms of dialysis disequilibrium syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute intradialytic hypotension:</span></strong><span style=\"font-size:12.0pt\"> This would typically cause dizziness, lightheadedness, or fainting, but not the neurologic symptoms described.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hemodialysis-associated thrombosis:</span></strong><span style=\"font-size:12.0pt\"> This would cause issues with the dialysis access site (e.g., pain, swelling, decreased blood flow) rather than neurologic symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Air embolism during hemodialysis:</span></strong><span style=\"font-size:12.0pt\"> This is a rare but serious complication that would present with sudden respiratory distress, chest pain, and potentially cardiac arrest.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To recognize the signs and symptoms of dialysis disequilibrium syndrome (DDS), a complication that can occur during the initial stages of hemodialysis in patients with uremia. DDS is caused by the rapid removal of urea, creating an osmotic gradient that leads to cerebral edema and neurological symptoms.</span></span></span></p>",
      "correct_choice_id": 81687,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20432,
      "choices": [
        {
          "id": 81689,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased potassium concentration </span></span></span></p>"
        },
        {
          "id": 81690,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased potassium concentration </span></span></span></p>"
        },
        {
          "id": 81691,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased calcium concentration </span></span></span></p>"
        },
        {
          "id": 81692,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased calcium concentration</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with secondary hyperparathyroidism due to end-stage renal disease undergoes a successful parathyroidectomy. During their first hemodialysis session post-surgery, which of the following dialysate modifications would be most appropriate?</span></span></p>",
      "unique_key": "Q4436194",
      "question_audio": null,
      "question_video": null,
      "map_id": 20429,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Increased calcium concentration</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">After parathyroidectomy for secondary hyperparathyroidism, patients are at risk of developing &quot;hungry bone syndrome&quot; (HBS). HBS is characterized by rapid and profound hypocalcemia due to the sudden removal of parathyroid hormone (PTH), which normally increases calcium levels. To compensate for this, the dialysate calcium concentration may be increased to prevent severe hypocalcemia and its associated complications, such as tetany and seizures.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A. Increased potassium</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>concentration</strong>:&nbsp;Not relevant to HBS management.&nbsp;Potassium levels may need to be adjusted based on the patient&#39;s serum potassium.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option B. Decreased potassium</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>concentration</strong>:&nbsp;This could worsen hypokalemia,&nbsp;which is not a primary concern in HBS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Decreased calcium concentration</span></strong><span style=\"font-size:12.0pt\">:&nbsp;This would exacerbate the existing hypocalcemia in HBS and should be avoided</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand the importance of modifying dialysate calcium concentration after parathyroidectomy in patients with secondary hyperparathyroidism due to end-stage renal disease. Increasing the calcium concentration helps prevent severe hypocalcemia and its associated complications, known as &quot;hungry bone syndrome&quot; (HBS).</span></span></span></p>",
      "correct_choice_id": 81691,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20433,
      "choices": [
        {
          "id": 81693,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Sirolimus </span></span></span></p>"
        },
        {
          "id": 81694,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Everolimus </span></span></span></p>"
        },
        {
          "id": 81695,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Belatacept </span></span></span></p>"
        },
        {
          "id": 81696,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basiliximab</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following immunosuppressive medications binds to CD80 and CD86 on antigen-presenting cells, inhibiting T-cell activation? </span></span></p>",
      "unique_key": "Q9775037",
      "question_audio": null,
      "question_video": null,
      "map_id": 20430,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Belatacept </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Belatacept is a costimulatory blockade agent that specifically targets the CD80/CD86-CD28 interaction, a crucial step in T-cell activation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Sirolimus:</span></strong><span style=\"font-size:12.0pt\"> Sirolimus (rapamycin) is an mTOR inhibitor. It works by forming a complex with FKBP-12, which then binds to and inhibits the mTOR protein, thus blocking T-cell proliferation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Everolimus:</span></strong><span style=\"font-size:12.0pt\"> Everolimus is also an mTOR inhibitor and has a similar mechanism of action to sirolimus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Basiliximab:</span></strong><span style=\"font-size:12.0pt\"> Basiliximab is a monoclonal antibody that binds to the IL-2 receptor on activated T cells, preventing their proliferation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand the different mechanisms of action of immunosuppressive medications used in transplantation. Belatacept is unique in its ability to specifically inhibit T-cell activation by blocking the interaction between CD80/CD86 on antigen-presenting cells and CD28 on T cells.</span></span></span></p>",
      "correct_choice_id": 81695,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20434,
      "choices": [
        {
          "id": 81697,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute tubular necrosis </span></span></span></p>"
        },
        {
          "id": 81698,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcineurin inhibitor toxicity </span></span></span></p>"
        },
        {
          "id": 81699,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute T-cell mediated rejection </span></span></span></p>"
        },
        {
          "id": 81700,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibody-mediated rejection</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old kidney transplant recipient, 3 weeks post-transplant, presents with a sudden rise in serum creatinine, decreased urine output, and tenderness over the allograft. Doppler ultrasound shows increased renal artery resistance. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q7037244",
      "question_audio": null,
      "question_video": null,
      "map_id": 20431,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Acute T-cell mediated rejection</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of the following factors strongly suggests acute T-cell mediated rejection:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Timing:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Occurs within the first few weeks to months after transplantation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clinical Presentation:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Sudden rise in creatinine,&nbsp;decreased urine output,&nbsp;and tenderness over the allograft.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Doppler Ultrasound:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Increased renal artery resistance is indicative of inflammation and edema in the rejecting kidney.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute tubular necrosis (ATN):</span></strong><span style=\"font-size:12.0pt\">&nbsp;ATN usually occurs immediately post-transplant and is less likely weeks later.&nbsp;It would not typically cause allograft tenderness or increased arterial resistance on Doppler.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Calcineurin inhibitor toxicity:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While this can cause elevated creatinine,&nbsp;it usually presents with more gradual onset and less specific symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Antibody-mediated rejection:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is less likely to occur early post-transplant and typically presents with more severe features like glomerulitis and vascular injury on biopsy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To recognize the clinical presentation and diagnostic findings of acute T-cell mediated rejection in kidney transplant recipients. This type of rejection typically occurs early post-transplant and presents with a sudden rise in creatinine, decreased urine output, allograft tenderness, and increased renal artery resistance on Doppler ultrasound. Differentiating this from other causes of graft dysfunction is crucial for prompt and appropriate intervention.</span></span></span></p>",
      "correct_choice_id": 81699,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20435,
      "choices": [
        {
          "id": 81701,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blood culture </span></span></span></p>"
        },
        {
          "id": 81702,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CMV PCR </span></span></span></p>"
        },
        {
          "id": 81703,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liver biopsy </span></span></span></p>"
        },
        {
          "id": 81704,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung biopsy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A kidney transplant recipient with a positive CMV IgG serostatus develops fever, leukopenia, and elevated liver enzymes 4 months post-transplant. Which of the following is the most appropriate diagnostic test to confirm CMV infection?</span></span></p>",
      "unique_key": "Q1688741",
      "question_audio": null,
      "question_video": null,
      "map_id": 20432,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) CMV PCR</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CMV PCR is the most sensitive and specific test for diagnosing CMV infection in transplant recipients. It can detect viral DNA in the blood, allowing for early diagnosis and treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Blood culture</span></strong><span style=\"font-size:12.0pt\">: Blood culture is not useful for diagnosing viral infections like CMV.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Liver biopsy</span></strong><span style=\"font-size:12.0pt\">: Liver biopsy is invasive and not typically needed for diagnosing CMV infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lung biopsy</span></strong><span style=\"font-size:12.0pt\">: Lung biopsy is not indicated in this scenario as the primary organ involvement is not the lungs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand that CMV PCR is the most sensitive and specific test for diagnosing CMV infection in transplant recipients, allowing for early detection and treatment to prevent complications.</span></span></span></p>",
      "correct_choice_id": 81702,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20436,
      "choices": [
        {
          "id": 81705,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytomegalovirus (CMV) &ndash; Valganciclovir </span></span></span></p>"
        },
        {
          "id": 81706,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pneumocystis jirovecii pneumonia (PJP) &ndash; Trimethoprim-sulfamethoxazole (TMP-SMX) </span></span></span></p>"
        },
        {
          "id": 81707,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Aspergillus fumigatus &ndash; Fluconazole </span></span></span></p>"
        },
        {
          "id": 81708,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Nocardia asteroides &ndash; Ganciclovir</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A kidney transplant recipient presents 3 months post-transplant with fever, dry cough, and shortness of breath. Chest X-ray reveals bilateral interstitial infiltrates. Which of the following is the most likely diagnosis and the drug of choice for its prophylaxis?</span></span></p>",
      "unique_key": "Q8855848",
      "question_audio": null,
      "question_video": null,
      "map_id": 20433,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Pneumocystis jirovecii pneumonia (PJP) &ndash; Trimethoprim-sulfamethoxazole (TMP-SMX)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Diagnosis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;The clinical presentation (fever,&nbsp;dry cough,&nbsp;shortness of breath) and chest X-ray findings (bilateral interstitial infiltrates) are characteristic of Pneumocystis jirovecii pneumonia (PJP),&nbsp;a common opportunistic infection in the early post-transplant period.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Prophylaxis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Trimethoprim-sulfamethoxazole (TMP-SMX) is the preferred prophylactic agent for PJP in transplant recipients.&nbsp;It is typically given for the first 6 months after transplantation and may be continued longer in high-risk patients.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cytomegalovirus (CMV) &ndash; Valganciclovir</span></strong><span style=\"font-size:12.0pt\">: Cytomegalovirus (CMV) is a common infection after transplantation,&nbsp;but it usually presents with nonspecific symptoms like fever and fatigue,&nbsp;and it does not typically cause the classic chest X-ray findings of PJP.&nbsp;Valganciclovir is used for CMV prophylaxis and treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Aspergillus fumigatus &ndash; Fluconazole</span></strong><span style=\"font-size:12.0pt\">: Aspergillus fumigatus is a mold infection that can cause pulmonary symptoms,&nbsp;but it is less common in the early post-transplant period.&nbsp;Fluconazole is an antifungal medication,&nbsp;not used for PJP prophylaxis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Nocardia asteroides &ndash; Ganciclovir</span></strong><span style=\"font-size:12.0pt\">: Nocardia asteroides is a bacterial infection that can cause pulmonary or disseminated disease,&nbsp;but it is less common than PJP in this setting.&nbsp;Ganciclovir is used for CMV prophylaxis and treatment</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To recognize the clinical presentation and chest X-ray findings of Pneumocystis jirovecii pneumonia (PJP) in kidney transplant recipients and to understand that trimethoprim-sulfamethoxazole (TMP-SMX) is the preferred prophylactic agent for PJP.</span></span></span></p>",
      "correct_choice_id": 81706,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20437,
      "choices": [
        {
          "id": 81709,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Infection </span></span></span></p>"
        },
        {
          "id": 81710,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignancy </span></span></span></p>"
        },
        {
          "id": 81711,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiovascular events </span></span></span></p>"
        },
        {
          "id": 81712,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Graft failure</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the leading cause of death in kidney transplant recipients?</span></span></p>",
      "unique_key": "Q3970707",
      "question_audio": null,
      "question_video": null,
      "map_id": 20434,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Cardiovascular events</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While all of the listed options are potential causes of death in kidney transplant recipients, cardiovascular events are the leading cause, accounting for approximately 29% of deaths in this population. This patient&#39;s presentation is concerning for post-transplant lymphoproliferative disorder (PTLD), a type of malignancy that is more common in transplant recipients due to immunosuppression. However, even with PTLD, cardiovascular events remain the most likely cause of death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Infection:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While infection is a significant cause of mortality in transplant recipients (18%),&nbsp;it is not as common as cardiovascular events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Malignancy</strong>: Malignancy, including PTLD, is also a concern for transplant recipients (17%), but it is still less common than cardiovascular events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Graft failure:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While graft failure can lead to death,&nbsp;it is not as frequent a cause as cardiovascular events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To understand that cardiovascular events are the leading cause of death in kidney transplant recipients, highlighting the importance of cardiovascular risk assessment and management in this population.</span></span></span></p>",
      "correct_choice_id": 81711,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}